Eli Lilly will pay up to $1.3bn for Superluminal Medicines to discover and progress small-molecule therapeutics for GPCR ...

Concerns around Ixchiq's safety profile in elderly individuals continue as travel-related chikungunya cases increase in the ...

With multiple novel therapies expected and the treatment paradigm shifting toward earlier intervention, the US EoE market ...

Basilea has acquired the global rights for Venatorx Pharmaceuticals’ ceftibuten-ledaborbactam etzadroxil, an antibiotic being ...

Apertura Gene Therapy has entered several licensing agreements to advance CNS treatments using its TfR1 CapX technology.

Amphastar has signed an exclusive license agreement with Anji for the development, production, use and commercialisation of 3 ...

PureTech's latest spinoff Celea Therapeutics was created to progress the former's lead respiratory IPF programme, ...

Ovarian cancer is one of the most challenging malignancies in oncology. Despite advances in diagnosis and treatment, it is ...

Insmed’s drug Brinsupri (brensocatib) has landed a double regulatory landmark win, becoming both the first marketed ...

Despite posting record Q2 growth for its blockbuster weight loss and diabetes drug tirzepatide, Eli Lilly is facing legal ...

This will be the first time the option has been taken up since it was introduced at the beginning of 2025, under the Medical ...

Fosun Pharma Industrial has entered a licence agreement to grant ex-China rights for its respiratory drug, XH-S004, to Expedition.